Skip to main content
OpenTrials
Completed

NCT Number: NCT05521256

A Research Study of a New Medicine NNC0113-6856 in Healthy Males

In this study NN0113-6856 will be given to humans for the first time. We will be looking into how safe different single doses of the new investigational product NNC0113-6856 is and we will measure its amount as well as the amount of specific parts of the new investigational product in blood. The study will look at the effects of different single doses of NNC0113-6856. This could either be as an oral dose (cohort 1 to 5) or one injection into the vein (intravenous [IV]-cohort). Participant will get the investigational product either as one or two tablets (oral dose in cohort 1 to 5) or as injection into the vein (IV cohort). The study will last for about 6-10 weeks (up to 14 weeks in case of rescheduling for stand-by participants).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Type 2 Diabetes

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male.
  • Aged 18-55 years (both inclusive) at the time of signing informed consent.
  • Body mass index between 20.0 and 27.0 kilogram per meter square (kg/m^2)(both inclusive).

Exclusion criteria

  • Glycated haemoglobin (HbA1c) greater than or equal to (>=) 6.5 percent (%) (48 millimoles per moles [mmol/mol]) at screening.
  • Use of tobacco and nicotine products, defined as any of the below:
  • Smoking more than 5 cigarettes or the equivalent per day.
  • Not willing to refrain from smoking and use of nicotine substitute products during the inpatient periods.
  • Presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.
  • History of major surgical procedures involving the stomach potentially affecting absorption of trial products (example: subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant
  • Presence or history of pancreatitis (acute or chronic).
  • Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
  • Any of the below laboratory safety parameters at screening outside the below laboratory range, see "Log of laboratory ranges used for laboratory parameter exclusion criterion" for specific values:
  • Alanine Aminotransferase (ALT) greater than (>) upper normal limit (UNL)
  • Aspartate aminotransferase (AST) > UNL
  • Bilirubin > UNL
  • Creatinine > UNL
  • International normalized ratio (INR) > UNL
  • Precence or history of hepatitis

Treatment and study plan

NNC0113-6856

Drug

Participants will receive NN0113-6856 orally or intravenously.

Placebo

Drug

Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts.

Primary outcomes

  1. Number of adverse events

    Time frame: From time of dosing (day 1) until completion of the follow-up visit (Day 42)

    Measured as number of events.

Secondary outcomes

  1. For oral cohorts- AUC0-tz,sema,single dose (SD): Area under the semaglutide plasma concentration-time curve from time 0 to tz after a single dose, where tz is the time of last quantifiable concentration

    Time frame: From pre-dose (day 1) to completion of follow-up visit (Day 42)

    Measured in hours*nanomoles per liter (h*nmol/L).

  2. For oral cohorts- AUC0-infinity (∞),sema,SD: Area under the semaglutide plasma concentration-time curve from time 0 to infinity after a single dose

    Time frame: From pre-dose (day 1) to completion of follow-up visit (Day 42)

    Measured in hours*nanomoles per liter (h*nmol/L).

  3. For oral cohorts- Cmax,sema,SD: Maximum observed plasma concentration of semaglutide after a single dose

    Time frame: From pre-dose (day 1) to completion of follow-up visit (day 42)

    Measured in nanomoles per liter (nmol/L).

  4. For oral cohorts- tmax,sema,SD: Time to maximum observed concentration of semaglutide after a single dose

    Time frame: From pre-dose (day 1) to completion of follow-up visit (day 42)

    Measured in hours (h).

  5. For oral cohorts- t½,sema,SD: Terminal half-life of semaglutide after a single dose

    Time frame: From pre-dose (day 1) to completion of follow-up visit (day 42)

    Measured in hours (h).

  6. For oral cohorts- AUC0-tz,6856,SD: Area under the NNC0113-6856 plasma concentration-time curve from time 0 to tz after a single dose, where tz is the time of last quantifiable concentration

    Time frame: From pre-dose (day 1) to completion of visit 5 (day 22)

    Measured in hours*nanomoles per liter (h*nmol/L).

  7. For oral cohorts- AUC0-∞,6856,SD: Area under the NNC0113-6856 plasma concentration-time curve from time 0 to infinity after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (day 22)

    Measured as hours*nanomoles per liter (h*nmol/L).

  8. For oral cohorts- Cmax,6856,SD: Maximum observed plasma concentration of NNC0113-6856 after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (day 22)

    Measured as nanomoles per liter (nmol/L).

  9. For oral cohorts- tmax,6856,SD: Time to maximum observed concentration of NNC0113-6856 after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in hours (h).

  10. For oral cohorts- t½,6856,SD: Terminal half-life of NNC0113-6856 after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in hours (h).

  11. For oral cohorts- AUC0-tz,4768,SD: Area under the NNC0113-4768 plasma concentration-time curve from time 0 to tz after a single dose, where tz is the time of last quantifiable concentration

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in hours*nanomoles per liter (h*nmol/L).

  12. For oral cohorts- AUC0-∞,4768,SD: Area under the NNC0113-4768 plasma concentration-time curve from time 0 to infinity after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in hours*nanomoles per liter (h*nmol/L).

  13. For oral cohorts- Cmax,4768,SD: Maximum observed plasma concentration of NNC0113-4768 after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in nanomoles per liter (nmol/L).

  14. For oral cohorts- tmax,4768,SD: Time to maximum observed concentration of NNC0113-4768 after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in hours (h).

  15. For oral cohorts- t½,4768,SD: Terminal half-life of NNC0113-4768 after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in hours (h).

  16. For intravenous (i.v.) cohort- AUC0-infinity (∞),sema,SD: Area under the semaglutide plasma concentration-time curve from time 0 to infinity after a single dose

    Time frame: From pre-dose (day 1) to completion of follow-up visit (day 42)

    Measured in hours*nanomoles per liter (h*nmol/L).

  17. For i.v. cohort- t½,sema,SD: Terminal half-life of semaglutide after a single dose

    Time frame: From pre-dose (day 1) to completion of follow-up visit (day 42)

    Measured in hours (h).

  18. For i.v. cohort- Cmax,sema,SD: Maximum observed plasma concentration of semaglutide after a single dose

    Time frame: From pre-dose (day 1) to completion of follow-up visit (day 42)

    Measured in nanomoles per liter (nmol/L).

  19. For i.v. cohort- AUC0-∞,6856,SD: Area under the NNC0113-6856 plasma concentration-time curve from time 0 to infinity after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (day 22)

    Measured as hours*nanomoles per liter (h*nmol/L)

  20. For i.v. cohort- t½,6856,SD: Terminal half-life of NNC0113-6856 after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (day 22)

    Measured in hours (h).

  21. For i.v. cohort- CL6856,SD: Total plasma clearance of NNC0113-6856 after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in liters per hour (L/h).

  22. For i.v. cohort- Vz6856,SD: Apparent volume of distribution of NNC0113-6856 after a single dose based on plasma concentration values

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in liters (L).

  23. For i.v. cohort- MRT6856,SD: Mean residence time for NNC0113-6856 after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in hours (h).

  24. For i.v. cohort- AUC0-infinity (∞),4768,SD: Area under the NNC0113-4768 plasma concentration-time curve from time 0 to infinity after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in hours*nanomoles per liter (h*nmol/L).

  25. For i.v. cohort- t½,4768,SD: Terminal half-life of NNC0113-4768 after a single dose

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in hours (h).

  26. For i.v. cohort and oral cohort- AUC0-∞,6856,SD/dose: Area under the NNC0113-6856 plasma concentration-time curve from 0 to infinity after a single dose divided by the dose administered

    Time frame: From pre-dose (day 1) to completion of visit 5 (Day 22)

    Measured in hours*nanomoles per liter per milligram (h*nmol/L/mg).

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

A First Human Dose Study Investigating Safety, Tolerability, and Pharmacokinetics of Oral Single Doses of NNC0113-6856 in Healthy Male Participants

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Aug 30, 2022
Registry last updated
Dec 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.